IRCT20150101020514N30招募中3 期
A phase III, randomized, two armed, double-blinded, parallel, active-controlled, non-inferiority clinical trial to compare efficacy and safety of Elletox(Nano Darou Pajuhan Pardis) versus Dysprot®(Ispen Co.) for correction of moderate to severe glabellar line
ano Darou Pajouhan Pardis Company0 个研究点目标入组 168 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 发起方
- 入组人数
- 168
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 years 至 65 years（—）
- 性别
- All
入选标准
- •Men and women with 18 to 65 years old
- •Mild to moderate Glabellar Lines
- •Signing informed consent form
排除标准
- •Allergies to botulinum toxin or any other compound in the formulation
- •Previous treatment with botulinum toxin within the last 6 months
- •History of filler injection in glabellar area during the last year
- •History of any alergic reaction to injectable fillers in the facial area
- •History of eyebrow tattoo or any other procedure in the eyebrow area during the last month
- •Planned Facial Cosmetic Surgery (such as filler injection, chemical peeling and laser) Using products that cause skin remodeling or active changes on the forehead area and History of any cosmetic surgery in glabellar area in the last 6 months
研究者
相似试验
招募中
3 期
Clinical trial to compare efficacy and safety of Abobotulinum toxin A(Espad Pharmed) versus Abobotulinum toxin A(Dysport®, Ipsen Co.)skin rejuvenation.IRCT20150101020514N23Espad pharmed Company146
已完成
3 期
Evaluation of efficacy and safety of Denosumab (produced by AryoGen Pharmed Co.) versus Denosumab (Xgeva®, produced by Amgen Co.)IRCT20150303021315N21AryoGen Pharmed Co.272
进行中（未招募）
不适用
Efficacy and Safety study comparing PRAVAFENIX (combination of fenofibrate and pravastatin) versus Atoravastatin in high coronary heart disease risk patients with mixed dyslipidaemiamixed dyslipidaemiaMedDRA version: 16.0Level: PTClassification code 10058108Term: DyslipidaemiaSystem Organ Class: 10027433 - Metabolism and nutrition disordersMedDRA version: 16.0Level: PTClassification code 10070901Term: Diabetic dyslipidaemiaSystem Organ Class: 10027433 - Metabolism and nutrition disordersMedDRA version: 16.0Level: PTClassification code 10007649Term: Cardiovascular disorderSystem Organ Class: 10007541 - Cardiac disordersEUCTR2012-000575-17-BGaboratoires SMB S.A.430
进行中（未招募）
不适用
Efficacy and safety study comparing PRAVAFENIX versus atorvastatin 20 mg in high coronary heart disease risk patients with mixed dyslipidaemiaEUCTR2012-000575-17-HRABORATOIRES SMB S.A.430
进行中（未招募）
不适用
Efficacy and safety study comparing PRAVAFENIX versus atorvastatin 20 mg in high coronary heart disease risk patients with mixed dyslipidaemiaEUCTR2012-000575-17-LVABORATOIRES SMB S.A.430